Cargando…
Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645418/ http://dx.doi.org/10.1186/2051-1426-3-S2-O8 |
| _version_ | 1782400809499099136 |
|---|---|
| author | Powderly, John Cote, Gregory Flaherty, Keith Szmulewitz, Russell Z Ribas, Antoni Weber, Jeffrey Loo, Deryk Baughman, Jan Chen, Francine Moore, Paul Bonvini, Ezio Vasselli, James Wigginton, Jon Cohen, Roger Burris, Howard Chmielowski, Bartosz |
| author_facet | Powderly, John Cote, Gregory Flaherty, Keith Szmulewitz, Russell Z Ribas, Antoni Weber, Jeffrey Loo, Deryk Baughman, Jan Chen, Francine Moore, Paul Bonvini, Ezio Vasselli, James Wigginton, Jon Cohen, Roger Burris, Howard Chmielowski, Bartosz |
| author_sort | Powderly, John |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645418 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46454182015-11-20 Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 Powderly, John Cote, Gregory Flaherty, Keith Szmulewitz, Russell Z Ribas, Antoni Weber, Jeffrey Loo, Deryk Baughman, Jan Chen, Francine Moore, Paul Bonvini, Ezio Vasselli, James Wigginton, Jon Cohen, Roger Burris, Howard Chmielowski, Bartosz J Immunother Cancer Oral Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645418/ http://dx.doi.org/10.1186/2051-1426-3-S2-O8 Text en Copyright © 2015 Powderly et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Oral Presentation Powderly, John Cote, Gregory Flaherty, Keith Szmulewitz, Russell Z Ribas, Antoni Weber, Jeffrey Loo, Deryk Baughman, Jan Chen, Francine Moore, Paul Bonvini, Ezio Vasselli, James Wigginton, Jon Cohen, Roger Burris, Howard Chmielowski, Bartosz Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 |
| title | Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 |
| title_full | Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 |
| title_fullStr | Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 |
| title_full_unstemmed | Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 |
| title_short | Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 |
| title_sort | interim results of an ongoing phase i, dose escalation study of mga271 (fc-optimized humanized anti-b7-h3 monoclonal antibody) in patients with refractory b7-h3-expressing neoplasms or neoplasms whose vasculature expresses b7-h3 |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645418/ http://dx.doi.org/10.1186/2051-1426-3-S2-O8 |
| work_keys_str_mv | AT powderlyjohn interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 AT cotegregory interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 AT flahertykeith interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 AT szmulewitzrussellz interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 AT ribasantoni interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 AT weberjeffrey interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 AT looderyk interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 AT baughmanjan interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 AT chenfrancine interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 AT moorepaul interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 AT bonviniezio interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 AT vassellijames interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 AT wiggintonjon interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 AT cohenroger interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 AT burrishoward interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 AT chmielowskibartosz interimresultsofanongoingphaseidoseescalationstudyofmga271fcoptimizedhumanizedantib7h3monoclonalantibodyinpatientswithrefractoryb7h3expressingneoplasmsorneoplasmswhosevasculatureexpressesb7h3 |